Till Aßmann

DDG, DGBT, EADV (European Academy of Dermatology and Venereology), AAD (American Academy of Dermatology)

Homey B, Schuppe HC, Assmann T, Vohr HW, Lauerma AI, Ruzicka T, Lehmann P. A local lymph node assay to analyse immunosuppressive effects of topically applied drugs. Eur J Pharmacol. 1997;325:199-207.

Schuppe HC, Homey B, Assmann T, Martens R, Ruzicka T.Topical tacrolimus for pyoderma gangrenosum. Lancet. 1998;35::832.

Homey B, Assmann T, Vohr HW, Ulrich P, Lauerma AI, Ruzicka T, Lehmann P, Schuppe HC. Topical FK506 suppresses cytokine and costimulatory molecule expression in epidermal and local draining lymph node cells during primary skin immune responses. J Immunol. 1998;160:5331-40.

Ruzicka T, Assmann T, Homey B. Tacrolimus: the drug for the turn of the millennium? Arch Dermatol. 1999;135:574-80.

Assmann T, Homey B, Ruzicka T. Applications of tacrolimus for the treatment of skin disorders. Immunopharmacology. 2000;47:203-13.

Assmann T, Homey B, Ruzicka T. Topical tacrolimus for the treatment of inflammatory skin diseases. Expert Opin Pharmacother. 2001;2:1167-75.

Homey B, Alenius H, Muller A, Soto H, Bowman EP, Yuan W, McEvoy L, Lauerma AI, Assmann T, Bunemann E, Lehto M, Wolff H, Yen D, Marxhausen H, To W, Sedgwick J, Ruzicka T, Lehmann P, Zlotnik A. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med. 2002;8:157-65.

Assmann T, Ruzicka T. New immunosuppressive drugs in dermatology (mycophenolate mofetil, tacrolimus): unapproved uses, dosages, or indications. Clin Dermatol. 2002;20:505-14.

Burchardt T, Assmann T, Schulte KW, Ruzicka T, Neumann NJ. Management of dermatologic industrial accidents. Skin burns by bitumen as an example. Hautarzt. 2003;54:376-7.

Plettenberg H, Assmann T, Ruzicka T. Childhood vitiligo and tacrolimus: immunomodulating treatment for an autoimmune disease. Arch Dermatol. 2003;139:651-4.

Assmann T, Becker-Wegerich P, Grewe M, Megahed M, Ruzicka T. Tacrolimus ointment for the treatment of vulvar lichen sclerosus. J Am Acad Dermatol. 2003;48:935-7.

Ruzicka T, Assmann T, Lebwohl M. Potential future dermatological indications for tacrolimus ointment. Eur J Dermatol. 2003;13:331-42.

Assmann T, Voss R, Ruzicka T, Megahed M. Therapy resistant pemphigus vulgaris. Combination therapy with methylprednisolone and doxycycline. Hautarzt. 2003;54:979-81.

Mang R, Assmann T, Megahed M, Ruzicka T, Stege H. Mondor's disease. Hautarzt. 2003;54:990-2.

Assmann T, Burchardt T, Becker J, Ruzicka T, Megahed M. Topical immunomodulators: a therapeutic option for oral cicatricial pemphigoid. Hautarzt. 2004;55:390-2.

Assmann T, Becker J, Ruzicka T, Megahed M. Topical tacrolimus for oral cicatricial pemphigoid. Clin Exp Dermatol. 2004;29:674-6.

von Schmiedeberg S, Artik S, Assmann T, Megahed M, Ruzicka T. Treatment of therapy-resistant acral ulcers with iloprost. Hautarzt. 2004;55:1150-3.

Mang R, Krahl D, Assmann T. [Dermoscopic changes in melanocytic nevi during use of melanotan II]. Hautarzt. 2012;63:880-4.

Assmann T, Krahl D, Mang R. Cutaneous sarcoidal granoloma after botulinum toxin type A injection. J Am acad Dermatol 2013; 69: e247-9.

Mang, R., Kremer, A., Lehmann, P. et al. Skabies – klinische Therapieresistenz auf Permethrin. Hautarzt (2021)

Lehmann P, Mang R, Assmann T, Kremer A. Clinical Resistance to Therapy. Dtsch Arztebl Int. 2022 Apr 1;119(13):234

Soares K, Assmann T, Kremer A, Mang R. Eigenanwendung eines „Muttermal-Entfernungs-Stifts“ [Self-administration of a "mole removal pen"]. Dermatologie (Heidelb). 2023 Mar;74(3):191-194.

Lehmann P, Kremer A, Assmann T, Mang R. Pruritic papules and nodules as sign of persistent scabies infestation despite treatment according to current guidelines evidence for treatment resistance to ivermectin, benzylbenzoat and permethrin proven by videomicroscopy. IDCases. 2023 Jan 9;31

Buchbeiträge

Ruzicka T, Assmann T, Reitamo S. Introduction. In :Tacrolimus Ointment (Ruzicka T, Reitamo S, (editors)). Springer, Berlin, pp V-VI, 2004.

Assmann T, Homey B, Ruzicka T. Tacrolimus as immunomodulator In: Tacrolimus Ointment (Ruzicka T, Reitamo S, (editors)). Springer, Berlin, pp 111-125, 2004.

Assmann T, Ruzicka T. Other potential dermatological indications for Tacrolimus. In: Tacrolimus Ointment (Ruzicka T, Reitamo S, (editors)). Springer, Berlin, pp. 213-231, 2004.

Mang, R., Kremer, A., Lehmann, P. and Assmann, T. (2020), Videodermoscopic clues for scabies diagnosis and assessment of therapeutic efficacy. JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 18: 1022-1024.

Mang, R., Kremer, A., Lehmann, P. et al. Skabies – klinische Therapieresistenz auf Permethrin. Hautarzt (2021)

Lehmann P, Mang R, Assmann T, Kremer A. Clinical Resistance to Therapy. Dtsch Arztebl Int. 2022 Apr 1;119(13):234

Soares K, Assmann T, Kremer A, Mang R. Eigenanwendung eines „Muttermal-Entfernungs-Stifts“ [Self-administration of a "mole removal pen"]. Dermatologie (Heidelb). 2023 Mar;74(3):191-194.

Lehmann P, Kremer A, Assmann T, Mang R. Pruritic papules and nodules as sign of persistent scabies infestation despite treatment according to current guidelines evidence for treatment resistance to ivermectin, benzylbenzoat and permethrin proven by videomicroscopy. IDCases. 2023 Jan 9;31



Mang, R., Kremer, A. & Assmann, T. Lichtschutzberatung für die Praxis . hautnah dermatologie 36, 32–37 (2020)

Mang, R., Kremer, A., Lehmann, P. et al. Skabies – klinische Therapieresistenz auf Permethrin. Hautarzt (2021)